

# Erel Joffe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6167962/publications.pdf>

Version: 2024-02-01

81  
papers

1,482  
citations

471509

17  
h-index

361022

35  
g-index

82  
all docs

82  
docs citations

82  
times ranked

2990  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.	6.2	1
2	PO-1170 Low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. <i>Radiotherapy and Oncology</i> , 2022, 170, S991-S992.	0.6	0
3	Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7560-7560.	1.6	0
4	Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7575-7575.	1.6	3
5	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 4003-4017.	7.0	15
6	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021, 137, 39-48.	1.4	38
7	How we treat mature B-cell neoplasms (indolent B-cell lymphomas). <i>Journal of Hematology and Oncology</i> , 2021, 14, 5.	17.0	16
8	Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. <i>Blood Advances</i> , 2021, 5, 345-351.	5.2	7
9	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3165-3173.	1.4	539
10	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	6.2	35
11	Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?. <i>Blood Advances</i> , 2021, 5, 4185-4197.	5.2	15
12	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	1.6	97
13	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. <i>Blood</i> , 2021, 138, 181-181.	1.4	14
14	Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV +) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study. <i>Blood</i> , 2021, 138, 623-623.	1.4	17
15	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2529-2529.	1.4	0
16	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 183-183.	1.4	8
17	Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence. <i>Blood</i> , 2021, 138, 3753-3753.	1.4	1
18	The Outcome of CLL Patients According to IGHV Mutational Status: An Israeli Perspective. <i>Blood</i> , 2021, 138, 4686-4686.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogressors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade. <i>Blood</i> , 2021, 138, 1402-1402.	1.4	0
20	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. <i>Blood</i> , 2021, 138, 2513-2513.	1.4	0
21	Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. <i>Blood</i> , 2021, 138, 4578-4578.	1.4	0
22	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e879-e890.	4.6	48
23	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	5.2	64
24	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	6.2	81
25	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3382-3390.	5.2	10
26	Kinetics of <sc>preâ€œmyelodysplastic</sc> syndromes blood values correlate with disease risk and survival. <i>Hematological Oncology</i> , 2020, 38, 782-791.	1.7	1
27	Grade 3A follicular lymphoma can be effectively controlled with very low-dose radiation therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1500-1503.	1.3	3
28	Positron-emission tomographyâ€œbased staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020, 126, 78-90.	2.8	21
29	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020, 136, 39-40.	1.4	3
30	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 17-18.	1.4	5
31	Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 46-47.	1.4	3
32	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population. <i>Blood</i> , 2020, 136, 50-51.	1.4	2
33	Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-38.	1.4	1
34	A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020, 136, 49-50.	1.4	1
35	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 2121-2129.	1.4	46
36	Radiotherapy is an Effective Definitive Treatment for Limited Stage Grade 3A Follicular Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1016-1017.	0.8	0

#	ARTICLE	IF	CITATIONS
37	OUTCOMES OF 180 PATIENTS WITH INDOLENT LYMPHOMAS TREATED WITH VERY LOW DOSE (4 GY) RADIATION THERAPY ALONE. <i>Hematological Oncology</i> , 2019, 37, 222-223.	1.7	2
38	CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB-ERA. <i>Hematological Oncology</i> , 2019, 37, 251-252.	1.7	0
39	GRADE 3A FOLLICULAR LYMPHOMA CAN BE EFFECTIVELY CONTROLLED WITH VERY LOW DOSE RADIATION THERAPY. <i>Hematological Oncology</i> , 2019, 37, 391-392.	1.7	0
40	INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP-LIKE REGIMENS. <i>Hematological Oncology</i> , 2019, 37, 264-266.	1.7	0
41	Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT). <i>Blood</i> , 2019, 134, 2826-2826.	1.4	2
42	High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2837-2837.	1.4	6
43	Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution. <i>Blood</i> , 2019, 134, 22-22.	1.4	7
44	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. <i>Blood</i> , 2019, 134, 1619-1619.	1.4	9
45	Outcomes of 210 Patients with Follicular and Marginal Zone Lymphomas Treated with 4 Gy of Radiation Therapy. <i>Blood</i> , 2019, 134, 2827-2827.	1.4	3
46	Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2904-2904.	1.4	2
47	Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic model. <i>Leukemia and Lymphoma</i> , 2018, 59, 2227-2232.	1.3	2
48	Persistently low lymphocyte counts after <scp>FCR</scp> therapy for chronic lymphocytic leukemia are associated with longer overall survival. <i>Hematological Oncology</i> , 2018, 36, 128-135.	1.7	6
49	Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 29-33.	2.4	14
50	Gender differences in mortality among statin users aged 80 years or more. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2018, 51, 882-888.	1.8	0
51	Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials. <i>European Journal of Haematology</i> , 2018, 101, 399-406.	2.2	5
52	Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. <i>European Journal of Haematology</i> , 2018, 101, 502-507.	2.2	6
53	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018, 8, 60.	6.2	25
54	The value of electrophysiologic study in decision-making regarding the need for pacemaker implantation after TAVI. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 48, 121-130.	1.3	36

#	ARTICLE	IF	CITATIONS
55	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. <i>Hematological Oncology</i> , 2017, 35, 734-740.	1.7	6
56	Clinical Trials in the Genomic Era. <i>Journal of Clinical Oncology</i> , 2017, 35, 1011-1017.	1.6	14
57	Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 654-654.	1.4	3
58	The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma. <i>Medicine (United States)</i> , 2016, 95, e2910.	1.0	27
59	Reduced-dose ICE chemotherapy + rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1633-1639.	1.3	12
60	Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance. <i>Leukemia and Lymphoma</i> , 2016, 57, 1382-1388.	1.3	10
61	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. <i>Blood</i> , 2016, 128, 2955-2955.	1.4	4
62	Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. <i>Haematologica</i> , 2015, 100, 662-669.	3.5	19
63	The relative contribution of urine extravasation to elevation of plasma creatinine levels in acute unilateral ureteral obstruction. <i>Canadian Urological Association Journal</i> , 2015, 9, 428.	0.6	9
64	Expert guided natural language processing using one-class classification. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 962-966.	4.4	14
65	Comparison of the Low Toxicity Tecam Conditioning Regimen to BEAM in Patients with Lymphoma Requiring Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3188-3188.	1.4	2
66	Absolute lymphocyte count with extreme hyperleukocytosis does not have a prognostic impact in chronic lymphocytic leukemia. <i>Anticancer Research</i> , 2015, 35, 2861-6.	1.1	3
67	Errors in after-hours phone consultations: a simulation study. <i>BMJ Quality and Safety</i> , 2014, 23, 398-405.	3.7	3
68	Recurrent hospitalizations with moderate to severe hyponatremia in older adults and its associated mortality. <i>European Journal of Internal Medicine</i> , 2014, 25, 624-628.	2.2	15
69	A benchmark comparison of deterministic and probabilistic methods for defining manual review datasets in duplicate records reconciliation. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 97-104.	4.4	26
70	Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrations. <i>Leukemia Research</i> , 2014, 38, 484-489.	0.8	8
71	Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience. <i>Blood</i> , 2014, 124, 5659-5659.	1.4	1
72	Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study. <i>Blood</i> , 2014, 124, 3488-3488.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome. <i>Blood</i> , 2014, 124, 2132-2132.	1.4	0
74	Evaluation of a Problem-Specific SBAR Tool to Improve After-Hours Nurse-Physician Phone Communication: A Randomized Trial. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2013, 39, 495-AP6.	0.7	25
75	Survival Prediction In High Dimensional Datasets – Comparative Evaluation Of Lasso Regularization and Random Survival Forests. <i>Blood</i> , 2013, 122, 1728-1728.	1.4	2
76	Optimized dual threshold entity resolution for electronic health record databases–training set size and active learning. <i>AMIA ... Annual Symposium proceedings</i> , 2013, 2013, 721-30.	0.2	4
77	Effect of vitamin D analogues on acute cardiorenal syndrome: a laboratory rat model. <i>Israel Medical Association Journal</i> , 2013, 15, 693-7.	0.1	3
78	Collaborative knowledge acquisition for the design of context-aware alert systems. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2012, 19, 988-994.	4.4	4
79	Duplicate patient records–implication for missed laboratory results. <i>AMIA ... Annual Symposium proceedings</i> , 2012, 2012, 1269-75.	0.2	9
80	C-reactive protein to distinguish pneumonia from acute decompensated heart failure. <i>Clinical Biochemistry</i> , 2009, 42, 1628-1634.	1.9	20
81	C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2009, 20, 518-521.	2.2	18